The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Non-Alcoholic Steatohepatitis Biomarkers Market Research Report 2024

Global Non-Alcoholic Steatohepatitis Biomarkers Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1743852

No of Pages : 97

Ask Your Query

Synopsis
Global Non-Alcoholic Steatohepatitis Biomarkers market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-Alcoholic Steatohepatitis Biomarkers market research.

Key companies engaged in the Non-Alcoholic Steatohepatitis Biomarkers industry include Genfit, Prometheus Laboratories, Siemens Medical Solutions USA, BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer and Bristol-Myers Squibb Company, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % value of Non-Alcoholic Steatohepatitis Biomarkers were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Non-Alcoholic Steatohepatitis Biomarkers market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Non-Alcoholic Steatohepatitis Biomarkers market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Genfit
  • Prometheus Laboratories
  • Siemens Medical Solutions USA
  • BioPredictive
  • Quest Diagnostics
  • AstraZeneca Plc.
  • Laboratory Corporation of America Holdings
  • Pfizer
  • Bristol-Myers Squibb Company
  • NGM Biopharmaceuticals
  • Gilead Sciences
  • Perspectum Diagnostics
  • One Way Liver SL
  • Enterome SA
  • Echosens SA
  • Cisbio Bioassays SAS
  • Celerion Inc.
  • Xeptagen SpA
  • Boehringer Ingelheim

Segment by Type

  • Hepatic Fibrosis Biomarkers
  • Serum Biomarkers
  • Oxidative Stress Biomarkers
  • Apoptosis Biomarkers
  • Others

Segment by Application

  • Hospital
  • Pharmaceutical Company
  • Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

The Non-Alcoholic Steatohepatitis Biomarkers report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hepatic Fibrosis Biomarkers
1.2.3 Serum Biomarkers
1.2.4 Oxidative Stress Biomarkers
1.2.5 Apoptosis Biomarkers
1.2.6 Others
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Pharmaceutical Company
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market Perspective (2018-2029)
2.2 Non-Alcoholic Steatohepatitis Biomarkers Growth Trends by Region
2.2.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Non-Alcoholic Steatohepatitis Biomarkers Historic Market Size by Region (2018-2023)
2.2.3 Non-Alcoholic Steatohepatitis Biomarkers Forecasted Market Size by Region (2024-2029)
2.3 Non-Alcoholic Steatohepatitis Biomarkers Market Dynamics
2.3.1 Non-Alcoholic Steatohepatitis Biomarkers Industry Trends
2.3.2 Non-Alcoholic Steatohepatitis Biomarkers Market Drivers
2.3.3 Non-Alcoholic Steatohepatitis Biomarkers Market Challenges
2.3.4 Non-Alcoholic Steatohepatitis Biomarkers Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis Biomarkers Players by Revenue
3.1.1 Global Top Non-Alcoholic Steatohepatitis Biomarkers Players by Revenue (2018-2023)
3.1.2 Global Non-Alcoholic Steatohepatitis Biomarkers Revenue Market Share by Players (2018-2023)
3.2 Global Non-Alcoholic Steatohepatitis Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis Biomarkers Revenue
3.4 Global Non-Alcoholic Steatohepatitis Biomarkers Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis Biomarkers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis Biomarkers Revenue in 2022
3.5 Non-Alcoholic Steatohepatitis Biomarkers Key Players Head office and Area Served
3.6 Key Players Non-Alcoholic Steatohepatitis Biomarkers Product Solution and Service
3.7 Date of Enter into Non-Alcoholic Steatohepatitis Biomarkers Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis Biomarkers Breakdown Data by Type
4.1 Global Non-Alcoholic Steatohepatitis Biomarkers Historic Market Size by Type (2018-2023)
4.2 Global Non-Alcoholic Steatohepatitis Biomarkers Forecasted Market Size by Type (2024-2029)
5 Non-Alcoholic Steatohepatitis Biomarkers Breakdown Data by Application
5.1 Global Non-Alcoholic Steatohepatitis Biomarkers Historic Market Size by Application (2018-2023)
5.2 Global Non-Alcoholic Steatohepatitis Biomarkers Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Non-Alcoholic Steatohepatitis Biomarkers Market Size (2018-2029)
6.2 North America Non-Alcoholic Steatohepatitis Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Non-Alcoholic Steatohepatitis Biomarkers Market Size by Country (2018-2023)
6.4 North America Non-Alcoholic Steatohepatitis Biomarkers Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis Biomarkers Market Size (2018-2029)
7.2 Europe Non-Alcoholic Steatohepatitis Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Non-Alcoholic Steatohepatitis Biomarkers Market Size by Country (2018-2023)
7.4 Europe Non-Alcoholic Steatohepatitis Biomarkers Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Size (2018-2029)
8.2 Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Alcoholic Steatohepatitis Biomarkers Market Size (2018-2029)
9.2 Latin America Non-Alcoholic Steatohepatitis Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Non-Alcoholic Steatohepatitis Biomarkers Market Size by Country (2018-2023)
9.4 Latin America Non-Alcoholic Steatohepatitis Biomarkers Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis Biomarkers Market Size (2018-2029)
10.2 Middle East & Africa Non-Alcoholic Steatohepatitis Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Non-Alcoholic Steatohepatitis Biomarkers Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-Alcoholic Steatohepatitis Biomarkers Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Genfit
11.1.1 Genfit Company Detail
11.1.2 Genfit Business Overview
11.1.3 Genfit Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.1.4 Genfit Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.1.5 Genfit Recent Development
11.2 Prometheus Laboratories
11.2.1 Prometheus Laboratories Company Detail
11.2.2 Prometheus Laboratories Business Overview
11.2.3 Prometheus Laboratories Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.2.4 Prometheus Laboratories Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.2.5 Prometheus Laboratories Recent Development
11.3 Siemens Medical Solutions USA
11.3.1 Siemens Medical Solutions USA Company Detail
11.3.2 Siemens Medical Solutions USA Business Overview
11.3.3 Siemens Medical Solutions USA Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.3.4 Siemens Medical Solutions USA Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.3.5 Siemens Medical Solutions USA Recent Development
11.4 BioPredictive
11.4.1 BioPredictive Company Detail
11.4.2 BioPredictive Business Overview
11.4.3 BioPredictive Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.4.4 BioPredictive Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.4.5 BioPredictive Recent Development
11.5 Quest Diagnostics
11.5.1 Quest Diagnostics Company Detail
11.5.2 Quest Diagnostics Business Overview
11.5.3 Quest Diagnostics Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.5.4 Quest Diagnostics Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.5.5 Quest Diagnostics Recent Development
11.6 AstraZeneca Plc.
11.6.1 AstraZeneca Plc. Company Detail
11.6.2 AstraZeneca Plc. Business Overview
11.6.3 AstraZeneca Plc. Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.6.4 AstraZeneca Plc. Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.6.5 AstraZeneca Plc. Recent Development
11.7 Laboratory Corporation of America Holdings
11.7.1 Laboratory Corporation of America Holdings Company Detail
11.7.2 Laboratory Corporation of America Holdings Business Overview
11.7.3 Laboratory Corporation of America Holdings Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.7.4 Laboratory Corporation of America Holdings Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.7.5 Laboratory Corporation of America Holdings Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.8.4 Pfizer Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.8.5 Pfizer Recent Development
11.9 Bristol-Myers Squibb Company
11.9.1 Bristol-Myers Squibb Company Company Detail
11.9.2 Bristol-Myers Squibb Company Business Overview
11.9.3 Bristol-Myers Squibb Company Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.9.4 Bristol-Myers Squibb Company Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.9.5 Bristol-Myers Squibb Company Recent Development
11.10 NGM Biopharmaceuticals
11.10.1 NGM Biopharmaceuticals Company Detail
11.10.2 NGM Biopharmaceuticals Business Overview
11.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.10.4 NGM Biopharmaceuticals Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.10.5 NGM Biopharmaceuticals Recent Development
11.11 Gilead Sciences
11.11.1 Gilead Sciences Company Detail
11.11.2 Gilead Sciences Business Overview
11.11.3 Gilead Sciences Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.11.4 Gilead Sciences Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.11.5 Gilead Sciences Recent Development
11.12 Perspectum Diagnostics
11.12.1 Perspectum Diagnostics Company Detail
11.12.2 Perspectum Diagnostics Business Overview
11.12.3 Perspectum Diagnostics Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.12.4 Perspectum Diagnostics Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.12.5 Perspectum Diagnostics Recent Development
11.13 One Way Liver SL
11.13.1 One Way Liver SL Company Detail
11.13.2 One Way Liver SL Business Overview
11.13.3 One Way Liver SL Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.13.4 One Way Liver SL Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.13.5 One Way Liver SL Recent Development
11.14 Enterome SA
11.14.1 Enterome SA Company Detail
11.14.2 Enterome SA Business Overview
11.14.3 Enterome SA Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.14.4 Enterome SA Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.14.5 Enterome SA Recent Development
11.15 Echosens SA
11.15.1 Echosens SA Company Detail
11.15.2 Echosens SA Business Overview
11.15.3 Echosens SA Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.15.4 Echosens SA Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.15.5 Echosens SA Recent Development
11.16 Cisbio Bioassays SAS
11.16.1 Cisbio Bioassays SAS Company Detail
11.16.2 Cisbio Bioassays SAS Business Overview
11.16.3 Cisbio Bioassays SAS Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.16.4 Cisbio Bioassays SAS Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.16.5 Cisbio Bioassays SAS Recent Development
11.17 Celerion Inc.
11.17.1 Celerion Inc. Company Detail
11.17.2 Celerion Inc. Business Overview
11.17.3 Celerion Inc. Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.17.4 Celerion Inc. Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.17.5 Celerion Inc. Recent Development
11.18 Xeptagen SpA
11.18.1 Xeptagen SpA Company Detail
11.18.2 Xeptagen SpA Business Overview
11.18.3 Xeptagen SpA Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.18.4 Xeptagen SpA Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.18.5 Xeptagen SpA Recent Development
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Detail
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Non-Alcoholic Steatohepatitis Biomarkers Introduction
11.19.4 Boehringer Ingelheim Revenue in Non-Alcoholic Steatohepatitis Biomarkers Business (2018-2023)
11.19.5 Boehringer Ingelheim Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock